Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 Infection
- 1 May 2008
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 24 (5), 685-694
- https://doi.org/10.1089/aid.2007.0127
Abstract
This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.Keywords
This publication has 53 references indexed in Scilit:
- A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST StudyPLoS Clinical Trials, 2006
- Personalised social care for adults with disabilities: a problematic concept for frontline practiceHealth & Social Care in the Community, 2006
- Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapyJournal of Antimicrobial Chemotherapy, 2005
- Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2005
- Weighted Phenotypic Susceptibility Scores Are Predictive of the HIV‐1 RNA Response in Protease Inhibitor–Experienced HIV‐1–Infected SubjectsThe Journal of Infectious Diseases, 2004
- Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureJournal of Medical Virology, 2003
- Enhanced Prediction of Lopinavir Resistance from Genotype by Use of Artificial Neural NetworksThe Journal of Infectious Diseases, 2003
- Baseline Antiretroviral Drug Susceptibility Influences Treatment Response in Patients Receiving Saquinavir-Enhancing TherapyHIV Research & Clinical Practice, 2001
- Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2000
- Patterns of Resistance Mutations Selected by Treatment of Human Immunodeficiency Virus Type 1 Infection with Zidovudine, Didanosine, and NevirapineThe Journal of Infectious Diseases, 2000